Free Trial

Surrozen (SRZN) Competitors

$11.21
+0.21 (+1.91%)
(As of 05/31/2024 ET)

SRZN vs. OCAX, LIFE, SGMO, DBVT, OMGA, BLUE, CGTX, ATHA, IGNY, and PLX

Should you be buying Surrozen stock or one of its competitors? The main competitors of Surrozen include OCA Acquisition (OCAX), aTyr Pharma (LIFE), Sangamo Therapeutics (SGMO), DBV Technologies (DBVT), Omega Therapeutics (OMGA), bluebird bio (BLUE), Cognition Therapeutics (CGTX), Athira Pharma (ATHA), Ignyte Acquisition (IGNY), and Protalix BioTherapeutics (PLX).

Surrozen vs.

OCA Acquisition (NASDAQ:OCAX) and Surrozen (NASDAQ:SRZN) are both small-cap unclassified companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership, valuation and community ranking.

38.2% of OCA Acquisition shares are owned by institutional investors. Comparatively, 66.6% of Surrozen shares are owned by institutional investors. 48.9% of OCA Acquisition shares are owned by company insiders. Comparatively, 43.5% of Surrozen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

OCA Acquisition has a beta of -0.01, suggesting that its stock price is 101% less volatile than the S&P 500. Comparatively, Surrozen has a beta of 0.88, suggesting that its stock price is 12% less volatile than the S&P 500.

OCA Acquisition has higher earnings, but lower revenue than Surrozen.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OCA AcquisitionN/AN/A-$2.48MN/AN/A
Surrozen$12.50M2.87-$43.04MN/AN/A

Surrozen's return on equity of -12.52% beat OCA Acquisition's return on equity.

Company Net Margins Return on Equity Return on Assets
OCA AcquisitionN/A -12.52% -5.06%
Surrozen N/A -85.54%-71.86%

Surrozen received 3 more outperform votes than OCA Acquisition when rated by MarketBeat users.

CompanyUnderperformOutperform
OCA AcquisitionN/AN/A
SurrozenOutperform Votes
3
16.67%
Underperform Votes
15
83.33%

In the previous week, OCA Acquisition had 2 more articles in the media than Surrozen. MarketBeat recorded 3 mentions for OCA Acquisition and 1 mentions for Surrozen. OCA Acquisition's average media sentiment score of 1.89 beat Surrozen's score of 0.94 indicating that Surrozen is being referred to more favorably in the news media.

Company Overall Sentiment
OCA Acquisition Positive
Surrozen Very Positive

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
OCA Acquisition
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Surrozen
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Summary

OCA Acquisition and Surrozen tied by winning 5 of the 10 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SRZN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SRZN vs. The Competition

MetricSurrozenBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$35.86M$2.87B$5.17B$7.99B
Dividend YieldN/A2.27%2.76%4.00%
P/E RatioN/A12.25110.1214.93
Price / Sales2.87304.562,386.0773.53
Price / CashN/A161.5335.4131.55
Price / Book1.196.315.544.59
Net Income-$43.04M-$45.89M$106.07M$213.90M
7 Day Performance7.28%-2.41%1.14%0.87%
1 Month Performance10.99%-1.25%0.65%1.82%
1 Year Performance17.56%-1.22%2.69%5.90%

Surrozen Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OCAX
OCA Acquisition
0 of 5 stars
$11.18
+1.2%
N/A+2.1%$75.35MN/A0.00147,000Short Interest ↑
Positive News
High Trading Volume
LIFE
aTyr Pharma
3.2673 of 5 stars
$1.80
flat
$23.67
+1,214.8%
-23.8%$124.22M$350,000.00-2.0056Short Interest ↓
Positive News
SGMO
Sangamo Therapeutics
1.3291 of 5 stars
$0.60
-3.7%
$5.67
+852.1%
-49.2%$123.51M$176.23M-0.32405Positive News
DBVT
DBV Technologies
2.3788 of 5 stars
$0.61
-0.7%
$3.33
+446.8%
-71.4%$117.57M$15.73M-1.45104Analyst Forecast
Stock Split
News Coverage
Gap Up
OMGA
Omega Therapeutics
1.8319 of 5 stars
$2.13
+0.5%
$10.00
+369.5%
-72.5%$117.48M$4.94M-1.2893Positive News
BLUE
bluebird bio
1.6105 of 5 stars
$0.97
-0.3%
$5.74
+494.4%
-74.5%$105.67M$3.60M-1.31323Gap Down
CGTX
Cognition Therapeutics
3.5138 of 5 stars
$2.55
-1.9%
$6.67
+161.4%
-21.7%$102.15MN/A-2.7725Analyst Forecast
Short Interest ↓
Analyst Revision
News Coverage
Positive News
ATHA
Athira Pharma
3.1937 of 5 stars
$2.64
+3.1%
$19.00
+619.7%
-4.7%$101.19MN/A-0.8765Short Interest ↓
Positive News
IGNY
Ignyte Acquisition
0 of 5 stars
$13.05
+14.5%
N/AN/A$95.00MN/A0.00N/AGap Down
High Trading Volume
PLX
Protalix BioTherapeutics
2.591 of 5 stars
$1.23
+4.2%
$10.00
+713.0%
N/A$90.18M$59.65M30.75208

Related Companies and Tools

This page (NASDAQ:SRZN) was last updated on 6/2/2024 by MarketBeat.com Staff

From Our Partners